BTC Plc expects to report data from a Phase 2a study of its oral multiple sclerosis treatment, Pleneva, in the first half of 2011. Meanwhile, it is making plans to take over US sales from Nycomed of two emergency care products in October, 2010. ---Subscribe to MedNous to access this article--- Research & University News
